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The aim of this study was to describe the changing pattern of mutational spectrum of β-thalassemia (β-thal) in the Lazio
region (Central Italy), as consequence of recent demographic variations. From 1994 until present, 256 immigrant subjects with
hemoglobin disorders (including 191 heterozygotes and 65 homozygotes or compound heterozygotes) coming from 44 diﬀerent
foreign countries, have been molecularly characterized. 14 β-globin gene mutations were identiﬁed and their frequencies reﬂect
diﬀerent ethnic origins: 8 of these mutations account for 76.97% of all molecular defects, while 6 of them are much rare,
representing less than 2% of the total. These data diﬀer, both in type and percentage, from the mutational spectrum detected
in the native population in 1995. Since a few defects are prevalent in each country, a proper strategy for the identiﬁcation of
mutations in immigrant individuals relies on the prior knowledge of their frequency in native ethnic group.
1.Introduction
The inherited disorders of hemoglobin (including structural
hemoglobin variants and α-a n dβ-thalassemias) show a
marked molecular variability in the diﬀerent ethnic groups
that mainly results from heterogeneous mutations occurring
at the α-a n dβ-globin loci. At present, more than 600 and
700mutationsinvolvingtheα-globinandtheβ-globingenes,
respectively, have been described worldwide [1].
In the Lazio region (Latium) of Central Italy, β-
thalassemia (β-thal) is relatively common among the native
population with a prevalence of 2.4% [2]. The “Centro
Studi Microcitemie Roma” (CSMR) has been leading since
35 years a prevention program of hemoglobinopathies and
thalassemias in Latium by a strategic plan including three
diﬀerent types of actions: information to the population,
healthy carriers detection, and genetic counselling for at-risk
couples [3].
The epidemiology of hemoglobin disorders has been
drastically changed since the early 1980s–1990s [4] when
a consistent and progressive migration from emerging
countries has started in Italy, particularly in Latium. For this
reason, it is fundamental to adopt novel strategies to include
immigrant people in each regional prevention program.
To this aim, to correctly evaluate the current mutational
spectrum of β-thal and structural hemoglobin variants in
Latium,acohortof256immigrantsubjectswithhemoglobin
disorders, who are now resident in the region, has been
molecularlycharacterized.Thesesubjectshavebeenanalyzed
by molecular studies, because they were carriers, partners of
couples at risk of having children aﬀected with Thalassemia
major or intermedia, or because they were aﬀected.
In addition, a comparison with a previous study that
analyzed 203 prospective at-risk couples, who were native
of Latium [5], has been carried out. This paper allows of
verifying the changes occurred at the molecular level in2 Advances in Hematology











America (n:7)3.66 n %
Hb S 41 21.47 4 36 1
IVS-I-110 (G→A) 30 15.71 27 3
Hb E 17 8.90 17
Cod 39
(CAG→TAG) 17 8.90 17
IVS-I-5 (G→A,
G→C) 16 8.38 14 2
IVS-I-6 (T→C) 11 5.76 8 1 2
Hb C 8 4.19 6 2
IVS-I-1 (G→A) 7 3.66 5 1 1
Cod 82-83 (-G) 3 1.57 3
Hb Knossos 3 1.57 3
Hb Lepore 3 1.57 2 1
IVS-II-848(C→A) 3 1.57 1 2
Cod 41-42(-TTCT) 2 1.05 2
Cod 51 (-C) 2 1.05 2
Deletional
mutations 84 . 1 9 1 2 4 1
Other abnormal
Hbs 94 . 7 1 3 2 3 1
Other rare
mutations 11 5.76 4 2 1 2 2
β-thal diagnostics in this region, and it is aimed at better
directing the proper strategy, adopting, if necessary, new
types of methodologies.
2.MaterialsandMethods
5722 individuals (including aﬀected patients, β-thal and
hemoglobinopathies carriers, and their partners with the
aim of detecting silent forms of thalassemia) have been
molecularly analyzed for the β-globin genes. Of these
subjects, 256 were immigrant who resulted β-thal carriers
or aﬀected individuals after hematological examination,
carried out by cell counter Advia 2120 Hematology Systems
(Bayer Health Care-Diagnostics Division-Milan, Italy) and
hemoglobin fractions study, carried out by Variant II (Bio-
Rad, Laboratories, Hercules, CA, USA). The study was
performedafterobtainingpatients’consent,allregisteroﬃce
data, and geographical provenience of the family.
Genomic DNA was extracted from peripheral EDTA
anticoagulatedwholebloodbysaltingout[6].Themolecular
analysis of the β-globin gene was carried out by several
PCR-based techniques (ARMS-PCR, gap-PCR, restriction
endonuclease analysis and direct DNA sequencing) accord-
ing to the defect to investigate. Since the most common β-
thal causative defects are point mutations [1], we prevalently
used the Ampliﬁcation Refractory Mutation System (ARMS)
[7]. To perform this analysis, allele-speciﬁc primers, useful
to selectively amplify the most common mutations that
are prevalent in the countries of origin of all patients,
were designed. Rare mutations were detected by genomic
direct sequencing (Beckman Coulter CEQ TM 8000 Genetic
Analysis System), using primers covering the full genomic
region of the β-globin gene [8].
3. Results
Between1994and2007,attheCSMR,atotalof167,235indi-
viduals has been examined by haematological, haemoglobin,
and biochemical analyses. Of this total number, 10, 353 were
immigrant, indicating a progressive increase in the above-
mentioned years (from 2.7% until 9.8%). Among the 10,353
individuals, 7869 resulted to be wild type while 2484 were
e i t h e rc a r r i e r so ra ﬀected [9]( Table 3(a)).
The 256 individuals, molecularly examined, were mainly
coming from East Europe (102 subjects: Albania was
included in this group for geographical reasons) and Africa
(86 subjects), and in lower amount from Asia (60 subjects)
and Central-Southern America (8 subjects). These 256
individuals were divided in 110 healthy β-thal carriers, 81
carriers of hemoglobin variants, and 65 homozygous or
compound heterozygous patients.
From familiar data involving 191 healthy carriers ana-
lyzed at our molecular biology laboratories from 1994
until present (110 healthy β-thal carriers and 81 carriers
of several hemoglobinopathies), 40.31% were coming from
East Europe, mainly from Albania; 30.37% from Africa,
mainly from Egypt and Central-Western Africa (Senegal,
Coted’Ivoire,Ghana,Nigeria,Congo,BurkinaFaso);25.65%
from Asia (Asian and Middle Eastern countries), mainly
from Bangladesh (Table 1).Advances in Hematology 3
Table 2: Interactions between diﬀerent alleles in the β globin genes (65 immigrant patients).
β0/β0 β0/β+ β+/β+ −β++ Hb variants
Cd 39 homozygous (4) Cd 39 / IVS-I 110 (2) IVS-I 110 homozygous (5) Hb S/Hb S (19)
Cd 39/IVS-I 1 (1) Cd 8/IVS-I 6 (1) IVS-I 110/Hb Knossos (1) Hb S/Hb C (3)
Cd 10/Cd 16 homozygous (1) Cd 41-42/IVS-I 1 (1) IVS-I 110/IVS-II 848 (2) Hb S/Cd 39 (1)
Cd 6 homozygous (1) IVS-I 1/IVS-I 110 (1) IVS-I 110/-87 (1) Hb S/IVS-I 110 (2)
Cd 39/Cd 82-83 (1) Hb Lepore/IVS-I 5 (1) IVS-I 110/Hb E (1) Hb S/Cd 82-83 (1)
Cd 51/Hb Lepore (1) IVS-I 6/-30 (1) Hb C homozygous (3)
Hb E homozygous (5)
Hb E/deletion (1)
IVS-I 6 homozygous (3)
IVS-I 5 homozygous (1)
Table 3
(a) Laboratory tests for provisional diagnosis (normal, anemic, iron
deﬁcient, carrier, and aﬀected individuals)






1994–2007 167.235 10.353 6.2 2484 24.0
(b) Molecular tests for deﬁnitive diagnosis (carriers and aﬀected individ-
uals)
Years Examined subjects (n) Immigrants
(n)%
1994–1998 950 26 2.74
1999–2003 2,047 93 4.54
2004–2008 2,725 137 5.03
1994–2008 5,722 256 4.47
This novel heterogeneous population of immigrants has
deeply modiﬁed the mutational spectrum of β-thal alleles
that was observed in this Italian region 14 years ago. In fact, a
previously reported study, carried out on 406 individuals of
Latiumdescendant,detected8morecommonmutations(Cd
39, IVSI-110, IVSII-745, IVSI-6, IVSI-1, IVSII-1, Frameshift
6, and Hb Lepore) that accounted for 93.4% of all β-
thal alleles in the region [5]. Conversely, the present paper
shows that 8 partially diﬀerent mutations (HbS, IVSI-110,
HbE, cod 39, IVSI-5, IVSI-6, HbC, and IVSI-1) account
for 76.97% of all β-globin molecular defects in the foreign
population (Table 1). Due to the wide ethnic heterogeneity
of these heterozygous subjects, other molecular defects were
detected. These include several abnormal hemoglobins (that
areusuallyrare),somedeletionalmutations(Sicilian,Indian,
Filipino, and a novel 12-bp deletion at the beginning of the
β globin second intron found in a woman of Indian descent
(10)) and other rare β thal alleles (Table 1).
A few of the most common mutations in Latium are
also present in patients originating from East Europe [10],
although with diﬀerent frequencies. In addition, some
particular hemoglobin variants such as HbS, that in Italy
are predominant only in Southern populations [11], were
also detected in 4 subjects accounting for 5.19% of the total
(Table 1).
In Asian and Middle-Eastern populations, the HbE is
mainly present [12] (17 subjects out of 49, corresponding to
34.69%) and the IVSI-5 (G→C) mutation [13]( 1 6s u b j e c t s
corresponding to 32.65%), that in Latium is present only in
the G→A variant with a frequency of 0.45% [5].
In African populations, the hemoglobin variants are the
most common alterations [14], including 36 subjects with
HbS (62.07%), 6 subjects with HbC (10.34%), and 3 subjects
with Hb Knossos [15] (5.17%) (Table 1).
All the mutations that have been detected in 191 healthy
carriers were also revealed in diﬀerent combinations in 65
relatives, who were homozygous or compound heterozygous
patients (Table 2).
4. Discussion
Latium is the Italian region with the highest incidence of
most recent immigration. From published data in 2009 by
Caritas/Osservatorio Romano sulle Migrazioni [16], out of a
total of 11.69% immigrants who are resident in Latium [17],
30.70% are coming from Romania, 6.81% from Philippines,
5.39% from Poland, 4.97% from Albania, 3.33% from
Ukraine, and 3.05% from Peru. These data do not perfectly
match with the ethnic variety of individuals who arrived at
our CSMR laboratory, for cultural, social, and also genetic
reasons. In fact, the Philippine population is absent in our
cohort of samples because in that country is prevalent the
α-thal and not the β-thal [18], while Romanians are less
represented for the rare presence (0.5%) of β-thal in that
country [19].
During the last 15 years, the number of molecular
analyses carried out at CSMR on foreign patients or healthy
carriershasbeenprogressivelyincreased;inaﬁve-yearperiod
(2004–2008) has been quintupled, if compared to the ﬁrst
ﬁve years (1994–1998) (Table 3(b)). Although a few and
very comprehensive studies have determined the inﬂuence of
recent immigration movements by updating the spectrum of
β-globin mutations in Northern and Western Europe, or in4 Advances in Hematology
the United Kingdom [20, 21], such a similar epidemiological
study regarding the changing spectrum of mutations in Italy
has not been carried out. This paper is aimed at fulﬁlling
this lack of information by determining the novel spectrum
of β-globin mutations observed in immigrant populations
in the Latium region from 1994 until present. In our
MolecularBiologyLaboratory,from1994topresent,wehave
detected 256 foreign subjects with hereditary hemoglobin
disorders (4.47% of the total molecular analysis carried out
in the considered 15 years) (Table 3(b)). If compared to the
molecular analyses carried out in 1995 and involving only
heterozygotes who were native of Latium [5], the present
research highlighted a wider heterogeneity of all mutations
in immigrant subjects. Although also in this cohort of indi-
viduals some mutations are more common, it is evident the
presence of structural hemoglobin variants that were absent
in the Latium population in the recent past. As expected,
a similar heterogeneity was also evident in carriers of two
molecular alterations (i.e., patients aﬀected with thalassemia
major, thalassemia intermedia, and hemoglobinopathies)
(Table 2).
The novel mutations that in the recent past were never
described in the Latium native population are obviously
common in the countries of origin of the immigrant β-
thal carriers; for example: cod 82-83 (-G) in Albania, cod
10 (C→A)/cod 16 (-C) in Afghanistan, cod 36-37 (-T) in
Santo Domingo, cod 41-42 (-TCTT) in Bangladesh, cod 51
(-C) in Romania, −29 (A→G) in Venezuela, and IVS II-
654 (C→T) in China. Regarding the hemoglobin variants,
that are considered of scarce clinical relevance in our region,
with the exception of the Hb Lepore (2.05%), the HbS is
more frequent in African descendant individuals, the HbE
is common in Asian subjects, while other variants such as
HbC, Hb Lepore, and Hb Knossos are evident in individuals
originating from countries in which these mutations are
common.
Finally,somevariantsthatarenotrelevantfromaclinical
point of view including Hb Kenitra in a subject from Nigeria,
Hb G-Coushatta in a Iranian subject, Hb Hoshida in an
Hungarian subject, have been detected by direct sequencing
of the β-globin gene.
Of course, all the detected molecular defects only par-
tially reﬂect the real variety that is present in each native
country [22].
Nowadays, a suitable strategy for identifying the β-
globin mutations needs the knowledge of the mutations,
common or rare, that are present in the ethnic group to
which the individuals under examination belong to. This
information simpliﬁes the diagnostic strategy because it
allows to design the appropriate allele-speciﬁc primers, the
digestion restriction enzymes, or the appropriate probes to
detect the mutations that are more common in the patient’s
country of origin. In addition, it is always fundamental to
perform family studies for the identiﬁcation of heterozygous
mutations, in the case of patients carrying the association
of two β-globin defects, and also for understanding the
segregation of diﬀerent genes that may modify the pheno-
type. The mutations that remain uncharacterized may be
detected by direct automatic sequencing analysis of genomic
DNA. It is becoming evident that in the present condition of
uninterruptedandconstantmigrationofforeignindividuals,
who are carriers of mutations that are rare in the Italian
indigenous population, the use of commercial kits is not
suﬃcient for the mutation detection in a such heterogeneous
cohort of subjects.
IntheLatiumregionofitscompetence,andstartingfrom
1994, the CSMR was able to reduce to zero the number
of aﬀected oﬀspring from unaware native couples, using a
protocol that included a mass screening of boys and girls (of
about13yearsold)whowereattendingthesecondaryschool.
This screening, joined to an adequate sanitary information,
has allowed the precocious identiﬁcation of healthy carriers.
In addition, postdiagnosis genetic counselling has been able
to give to the couples at risk all the medical information
and the alternative options of prevention. In this way, all
the informed carriers may decide by themselves according to
their ethical or religious opinions.
Today, the main objective of CSMR is to inform also the
foreign population of the risk [22, 23] and the possibility
of prevention [24] to provide means of hematological and
molecular diagnosis and to oﬀer a proper service of genetic
counselling.
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